Key Insights

Highlights

Success Rate

85% trial completion

Published Results

28 trials with published results (38%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

12.3%

9 terminated out of 73 trials

Success Rate

84.7%

-1.8% vs benchmark

Late-Stage Pipeline

36%

26 trials in Phase 3/4

Results Transparency

56%

28 of 50 completed with results

Key Signals

28 with results85% success

Data Visualizations

Phase Distribution

53Total
Not Applicable (8)
Early P 1 (2)
P 1 (2)
P 2 (15)
P 3 (20)
P 4 (6)

Trial Status

Completed50
Terminated9
Unknown7
Active Not Recruiting2
Recruiting2
Withdrawn2

Trial Success Rate

84.7%

Benchmark: 86.5%

Based on 50 completed trials

Clinical Trials (73)

Showing 20 of 20 trials
NCT06144151RecruitingPrimary

A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity

NCT07403812Not ApplicableNot Yet RecruitingPrimary

Assessing DCog Short for Neurotoxicity in CAR-T

NCT07333976Phase 2Completed

o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

NCT04150913Phase 2Completed

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

NCT00978458Phase 3Active Not Recruiting

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT03089905Phase 3Active Not Recruiting

A Study to Compare the Long-term Outcomes After Two Different Anaesthetics

NCT04614987TerminatedPrimary

Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy

NCT03461445Phase 4Completed

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

NCT03823768Phase 4CompletedPrimary

Envarsus Neurotoxicity Burden in Liver Transplant Patients

NCT05510596Not ApplicableCompleted

Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome

NCT05089604Phase 4Recruiting

Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations

NCT05094154Phase 4Completed

Effect of Antibiotic Choice On ReNal Outcomes (ACORN)

NCT06021262Unknown

Assessment of Nerve Damage Biomarkers in Acute and Chronic Organophosphate Toxicity

NCT05950386Unknown

Effects of Lead Exposure on Ferroptosis Pathway

NCT01399372Phase 2Completed

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT05798884Not ApplicableUnknown

Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients

NCT03628300CompletedPrimary

Neurotoxicity Evaluation of Beta-lactams in Intensive Care Unit and Identification of the Risk Factors

NCT01099449Phase 3Completed

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

NCT01372774Phase 3Completed

Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery

NCT05040230Completed

EEG Encephalopathy Patterns in Immune Effectors Cells-associated Neurotoxicity Syndrome (ICANS)Lay Language

Scroll to load more

Research Network

Activity Timeline